The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis
Joint Authors
Stokes, William
Clement, Fiona
Fenton, Carol
James, Matthew
Ronksley, Paul
Tang, Karen L.
Source
Canadian Journal of Gastroenterology and Hepatology
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-03-06
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
The recommended therapy for patients with chronic hepatitis C (CHC), genotype 1, who have cirrhosis and have failed prior therapy is 12 weeks of sofosbuvir (SOF), ledipasvir (LDV), and ribavirin (RBV).
This recommendation is based on expert opinion, and the efficacy of 12 weeks of SOF/LDV compared to SOF/LDV/RBV in this patient population has not yet been established.
Methods.
We conducted a systematic review and meta-analysis.
Two investigators independently searched electronic databases and relevant conference proceedings for randomized controlled trials comparing rates of sustained virologic response 12 weeks after therapy (SVR12) when using 12 weeks of SOF/LDV versus 12 weeks of SOF/LDV/RBV in patients with CHC, genotype 1, who have cirrhosis and failed previous therapy.
Results.
Our search strategy yielded 596 studies of which four met criteria for inclusion.
The pooled RR of not achieving SVR12 with SOF/LDV versus SOF/LDV/RBV was 1.21 (95% CI: 0.42–3.48).
Adverse events were lower in the SOF/LDV compared to the SOF/LDV/RBV arms (pooled RR: 0.11, 95% CI: 0.04–0.29).
Conclusions.
Our findings suggest that 12 weeks of SOF/LDV cannot be considered noninferior to 12 weeks of SOF/LDV/RBV to achieve SVR12 in patients with CHC who have cirrhosis and failed prior therapy.
American Psychological Association (APA)
Stokes, William& Fenton, Carol& Clement, Fiona& James, Matthew& Ronksley, Paul& Tang, Karen L.. 2017. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology،Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1141453
Modern Language Association (MLA)
Stokes, William…[et al.]. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology No. 2017 (2017), pp.1-8.
https://search.emarefa.net/detail/BIM-1141453
American Medical Association (AMA)
Stokes, William& Fenton, Carol& Clement, Fiona& James, Matthew& Ronksley, Paul& Tang, Karen L.. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology. 2017. Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1141453
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141453